Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5271430 | 0.94 | PLA2G4B (0.54) | PLA2G4BLTB4RLTB4R2ALOX15TBXAS1 | |
| SCHEMBL5266596 | 0.90 | PLA2G4B (0.56) | PLA2G4BLTB4RLTB4R2ALOX15TBXAS1 | |
| SCHEMBL14844426 | 0.84 | LTA4H (0.53) | ESR1ESRRG | |
| SCHEMBL11684213 | 0.79 | PLA2G4B (0.69) | CA2CAMK2APLA2G4BLTB4RLTB4R2 | |
| SCHEMBL27834238 | 0.78 | CA2 (0.83) | CA2CAMK2AESR1ALDH1A1LMNA | |
| SCHEMBL11683055 | 0.78 | PLA2G4B (0.61) | CA2CAMK2APLA2G4BLTB4RLTB4R2 | |
| 3-Hydroxyphenylacetate SCHEMBL5628662 | 0.78 | PLA2G4B (0.50) | PLA2G4BLTB4R | |
| SCHEMBL5271770 | 0.77 | PLA2G4B (0.55) | PLA2G4BLTB4RALDH1A1 | |
| SCHEMBL7400264 | 0.77 | FFAR1 (0.50) | CA2CAMK2APLA2G4BLTB4RLTB4R2 | |
| SCHEMBL10610940 | 0.76 | GAA (0.58) | CA2ESR1ESRRGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | CA2 3043/4885CAMK2A 3897/4885PLA2G4B 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.